• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

催乳素瘤的临床侵袭性:与侵袭及复发的相关性

Clinical aggression of prolactinomas: correlations with invasion and recurrence.

作者信息

Popescu Mihaela N, Ionescu Elena, Iovănescu L C, Cotoi B V, Popescu A I, Gănescu Anca Elena, Glodeanu Adina, Geormăneanu Cristiana, Moraru Andreiana, Pătraşcu Anca

机构信息

Department of Endocrinology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania;

出版信息

Rom J Morphol Embryol. 2013;54(4):1075-80.

PMID:24399004
Abstract

Some hypophyseal adenomas are discrete, well-marked lesions, which can be curatively removed by surgical resection, while others seem aggressive, invasive, recidive-prone, most often progressing in spite of any pharmacological, surgical or radiotherapeutical interventions. There is also a great variability within the incidence of aggression and invasion among the various types of hypophyseal immunotypes. Despite their well-differentiated nature and their "benign" constitution, an important number of hypophyseal tumors will be surely invasive within the sclerous, osseous and neural structures. Because the aggressive behavior of invasive adenomas is generally resolved by surgical treatment, this aspect of their biology does not perfectly reflect within their histopathological aspect. In fact, the invasive tumors with local extreme aggression are most often deceiving due to their relatively harmless histopathological aspect. The usual morphological signs of tumor aggression, namely pleomorphism, nuclear atypia, hemorrhage, high cellular and mitotic activity, poorly correlate with the invasive potential of pituitary tumors, with their proliferation capacity, their tendency of post-surgical recurrence or with their global biological behavior.

摘要

一些垂体腺瘤是界限清楚、特征明显的病变,可通过手术切除治愈,而另一些则似乎具有侵袭性、易复发,尽管采取了任何药物、手术或放射治疗干预措施,仍常常进展。在各种垂体免疫类型中,侵袭和侵犯的发生率也存在很大差异。尽管垂体瘤具有分化良好的性质和“良性”构成,但相当数量的垂体瘤肯定会侵犯硬脑膜、骨质和神经结构。由于侵袭性腺瘤的侵袭性行为通常通过手术治疗得到解决,其生物学的这一方面在组织病理学方面并未得到完美体现。事实上,具有局部极端侵袭性的侵袭性肿瘤由于其相对无害的组织病理学表现,常常具有欺骗性。肿瘤侵袭的常见形态学征象,即多形性、核异型性、出血、高细胞活性和有丝分裂活性,与垂体肿瘤的侵袭潜能、增殖能力、术后复发倾向或整体生物学行为相关性较差。

相似文献

1
Clinical aggression of prolactinomas: correlations with invasion and recurrence.催乳素瘤的临床侵袭性:与侵袭及复发的相关性
Rom J Morphol Embryol. 2013;54(4):1075-80.
2
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.微染色体维持蛋白 7 作为垂体腺瘤患者肿瘤侵袭性的预后标志物。
Eur J Endocrinol. 2016 Mar;174(3):307-14. doi: 10.1530/EJE-15-0586. Epub 2015 Nov 30.
3
Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.泌乳素瘤的临床与组织学相关性,特别提及对溴隐亭的耐药性。
Acta Neurochir (Wien). 2005 Jul;147(7):751-7; discussion 757-8. doi: 10.1007/s00701-005-0498-2. Epub 2005 Mar 14.
4
The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.Ki-67 增殖指数、P53 表达、有丝分裂指数和影像学肿瘤侵袭在垂体腺瘤中的预后作用。
Endocr Pathol. 2019 Mar;30(1):49-55. doi: 10.1007/s12022-018-9563-2.
5
Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.巨大垂体腺瘤:病理-影像学相关性及 p53 和 MIB-1 标记物的作用缺失。
Am J Surg Pathol. 2011 Aug;35(8):1204-13. doi: 10.1097/PAS.0b013e31821e8c96.
6
Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.无功能(静止性)垂体腺瘤的临床肿瘤生长及其与增殖标志物的比较
Exp Clin Endocrinol Diabetes. 2008 Feb;116(2):80-5. doi: 10.1055/s-2007-991131. Epub 2007 Dec 10.
7
Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior.垂体腺瘤。细胞学表现与生物学行为的相关性。
Acta Cytol. 1995 Sep-Oct;39(5):887-92.
8
p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.垂体腺瘤和癌中p53的表达:与侵袭性和肿瘤生长分数的相关性
Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1.
9
Pathobiology of pituitary adenomas and carcinomas.垂体腺瘤与癌的病理生物学
Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53. doi: 10.1227/01.NEU.0000223437.51435.6E.
10
Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.123例泌乳素分泌型垂体腺瘤的临床病理研究,特别关注腺瘤的多激素分泌及克隆性。
Cancer. 2002 Jul 15;95(2):258-66. doi: 10.1002/cncr.10676.

引用本文的文献

1
Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.侵袭性垂体腺瘤的分子诊断与药物治疗策略进展
Immun Inflamm Dis. 2024 Dec;12(12):e70098. doi: 10.1002/iid3.70098.
2
Diagnosis and Management of Aggressive/Refractory Growth Hormone-Secreting Pituitary Neuroendocrine Tumors.侵袭性/难治性生长激素分泌型垂体神经内分泌肿瘤的诊断与管理
Int J Endocrinol. 2024 Aug 26;2024:5085905. doi: 10.1155/2024/5085905. eCollection 2024.
3
Predictive value of cyst/tumor volume ratio of pituitary adenoma for tumor cell proliferation.
垂体腺瘤的囊/肿瘤体积比对肿瘤细胞增殖的预测价值。
BMC Med Imaging. 2024 Mar 21;24(1):69. doi: 10.1186/s12880-024-01246-z.
4
Refractory pituitary adenoma: a novel classification for pituitary tumors.难治性垂体腺瘤:一种垂体肿瘤的新分类
Oncotarget. 2016 Dec 13;7(50):83657-83668. doi: 10.18632/oncotarget.13274.
5
Whole-exome sequencing identifies variants in invasive pituitary adenomas.全外显子组测序可识别侵袭性垂体腺瘤中的变异。
Oncol Lett. 2016 Oct;12(4):2319-2328. doi: 10.3892/ol.2016.5029. Epub 2016 Aug 16.
6
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?泌乳素瘤中多巴胺激动剂治疗的撤药:哪些患者以及何时撤药?
Pituitary. 2016 Jun;19(3):303-10. doi: 10.1007/s11102-016-0708-3.
7
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.卡麦角林治疗的泌乳素瘤患者当前的药物撤药策略:一项系统评价和荟萃分析。
Pituitary. 2015 Oct;18(5):745-51. doi: 10.1007/s11102-014-0617-2.
8
Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.分泌型卷曲相关蛋白4在侵袭性垂体腺瘤中的低表达
Pituitary. 2015 Jun;18(3):335-42. doi: 10.1007/s11102-014-0579-4.